MajorAntiplatelet agents – P2Y12 receptor inhibitors×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The active metabolite of clopidogrel irreversibly blocks the platelet P2Y12 receptor. Platelets exposed to it stay affected for the rest of their lifespan, about 7–10 days (clopidogrel SmPC, EMA). According to the clopidogrel SmPC, combining clopidogrel with oral anticoagulants may make bleeding more severe (EMA). In the ENGAGE AF-TIMI 48 study in non-valvular atrial fibrillation, patients taking edoxaban were allowed thienopyridine monotherapy, such as clopidogrel. Clinically relevant bleeding increased, although the risk of bleeding was lower with edoxaban than with warfarin (edoxaban SmPC, EMA).
Symptoms
The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, bleeding into the skin and soft tissues, and vaginal bleeding (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). In people taking clopidogrel, bleeding may last longer than usual (clopidogrel SmPC, EMA).
Management
The combination is not contraindicated. The clopidogrel summary of product characteristics (SmPC), however, does not recommend combining clopidogrel with oral anticoagulants, edoxaban included, because bleeding may become more severe (clopidogrel SmPC, European Medicines Agency, EMA). Experience with edoxaban and dual antiplatelet therapy is very limited (edoxaban SmPC, EMA). Monitor patients taking clopidogrel closely for any sign of bleeding, including hidden bleeding, especially in the first weeks of treatment and after surgery. If symptoms suggest bleeding, promptly decide whether a full blood count and other tests are needed (clopidogrel SmPC, EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). Before elective surgery, if an antiplatelet effect is not needed, stop clopidogrel 7 days in advance (clopidogrel SmPC, EMA). If anticoagulation has to be interrupted, stop edoxaban as early as possible, preferably at least 24 hours before the procedure (edoxaban SmPC, EMA). According to the US edoxaban label, promptly evaluate any sign or symptom of blood loss in patients who also take other platelet aggregation inhibitors (edoxaban prescribing information, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica Plavix 75 mg comprimidos recubiertos con película (clopidogrel) (2022)– AEMPS CIMA, ficha técnica Plavix 75 mg, nº registro 98069001 (EU/1/98/069), texto EMA, revisión diciembre 2022, secciones 4.2, 4.4 y 4.5
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2